

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/74336 A1

(51) International Patent Classification⁷: **A61K 9/28**

(21) International Application Number: PCT/SE01/00626

(22) International Filing Date: 23 March 2001 (23.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0001151-0 31 March 2000 (31.03.2000) SE

(71) Applicant (for all designated States except US): **AMARIN DEVELOPMENT AB** [SE/SE]; Lundavägen 151, S-212 24 Malmö (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KENDRUP, John** [SE/SE]; Tegelbruksvägen 165, S-238 39 Oxie (SE). **FYHR, Peter** [SE/SE]; Löjtnantsvägen 9, S-237 32 Bjärred (SE).

(74) Agent: **AWAPATENT AB**; Box 5117, S-200 71 Malmö (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations except US

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR PRODUCING A CONTROLLED-RELEASE PREPARATION

(57) Abstract: The invention concerns a method for producing a controlled-release pharmaceutical preparation with a particle-containing coating, the coating being derived from an aqueous dispersion of a film-forming water insoluble polymer and a water soluble pore-forming agent. By suspending, instead of dissolving the pore-forming agent, the resulting coating will contain particles of the pore-formers with a predetermined size that creates, when disintegrated or dissolved in the body fluid, canals or a network of pores through the polymer film. Due to this network, the film will get a good mechanical stability and are left intact after the release of the drug.

WO 01/74336 A1

METHOD FOR PRODUCING A CONTROLLED-RELEASE PREPARATION

FIELD OF THE INVENTION

The present invention concerns a method for producing a pharmaceutical preparation. Specifically the invention concerns a method for producing a controlled-release pharmaceutical preparation with a particle-containing coating. The invention also concerns new pharmaceutical preparations.

BACKGROUND OF THE INVENTION

Many polymers are used as coatings in controlled release oral pharmaceutical preparations. These polymers are essentially water-insoluble and have consequently low permeability towards water and drugs. If the drug is very soluble and surface of the preparation is large, as in e.g. pellets, low permeability is desired. If the drug is moderately soluble or the surface of the preparation is small, as in e.g. tablets, the permeability of the coating has to be increased.

One method of increasing the permeability of the polymer is disclosed in the US patent 4 629 619. According to this patent the permeability is increased by including water soluble particles in the coating. When the preparation is subsequently swallowed by a patient and contacted with the GI juices, the water soluble particles dissolve and form pores or channels in the coating through which pores or channels the drug is released from the preparation. The coating including these water soluble pore-forming particles is obtained by a method according to which the water-soluble particles are suspended in an organic solvent. Medical preparations developed according to this patent are currently used and well accepted by the patients. A disadvantage is however the necessity to use organic solvents.

Another method of increasing the permeability is disclosed in the US patent 5 472 712 and 5 639 476. Ac-

according to these two patents the permeability of the polymer is increased by including a water-soluble material in the polymer. The coating including the water soluble material is obtained by dissolving the water soluble material in the aqueous dispersion of a film-forming polymer. When such a preparation is subsequently swallowed and contacted with the GI juices the water soluble material dissolves and make the polymer coating micro-porous and increase the release rate of the drug through the coating. The sizes of the micro-pores correspond to those of the dissolved molecules. An advantage with medical preparations prepared according to these two patents is that they may be prepared without organic solvent. A disadvantage is that the mechanical strength of the coating is poor, when the permeability is increased to an acceptable level for moderately soluble drugs, especially for tablets. Another disadvantage is that the size of the pores is not controlled which means e.g. that it is difficult to obtain reproducible products.

The permeability increasing or pore-forming agents used according to the two above methods may be identical chemically but the physical state of these agents in the coating solution is different.

OBJECT OF THE INVENTION

An object of the present invention is therefore to accomplish a method for producing a controlled-release pharmaceutical preparation having the same effective release rate and mechanical strength as the one described in US 4,557,925 while avoiding the use of organic solvents and the problems arising by using the method according to US 5,472,712 and 5 639 476.

SUMMARY OF THE INVENTION

This object as well as other objects that will be apparent from the description below, have now been obtained according to the present invention by providing a method for producing an essentially zero order, con-

trolled-release pharmaceutical preparation with a particle containing coating according to claim 1.

This method comprises the steps of:

- preparing a drug-containing solid core;
- 5 suspending a pore-forming agent having a balanced solubility in an aqueous dispersion of a film-forming, water insoluble polymer in order to form a coating suspension having a predetermined amount of solid particles of the pore-forming agent suspended therein;
- 10 coating the solid core with the obtained suspension; and drying the coated tablet.

By a careful selection of the type, amount and particle size of the pore-forming agent, the coating of the final tablet will contain comparatively large particles

15 of the pore-formers. When the tablet is then contacted with the GI juices of a patient, these particles dissolve and create a network of canals or pores of a predetermined size in the polymer coating and the drug is released through these pores or canals. Due to this network

20 the coating will get good mechanical stability and the polymer film will be left intact after the release of the drug.

A predetermined release rate may be obtained by selecting the above parameters of the pore-forming agent in

25 combination with type and amount of film forming polymer. The coatings thus prepared have a good mechanical stability and are left intact after the release of the drug and the pore-forming agent.

The problem to be solved by the present invention is

30 thus to find a pore-creating agent or pore-former combining the two seemingly non compatible properties of being, on one hand sufficiently insoluble in the aqueous coating dispersion, and on the other hand sufficiently soluble in the aqueous GI juices. In this context this feature is

35 referred to as "balanced solubility".

DETAILED DESCRIPTION OF THE INVENTION

The critical pore-forming agent must be a pharmaceutically acceptable substance that can be added to the aqueous dispersion of the film-forming polymer without
5 being completely dissolved. Important factors for the pore-forming agent are its solubility and mean particle size. The solubility of the pore-forming agent is below 200 mg/ml in the coating solution at 25°C. Preferably the solubility is below 100 mg/ml, more preferably below 50
10 and most preferably below 30 mg/ml.

The mean particle size of the pore-forming agent when added to the coating solution is 0.1-500 μm , preferably 0.5-100 μm and most preferably 1.0-25 μm .

If larger particles are used it will be difficult to
15 get reproducible preparations and if smaller particles are used manufacturing problems are expected.

The predetermined amount of solid particles of the pore-forming agent in the coating solution is selected by the man skilled in the art in view of the specific drug
20 and polymer used and the desired release rate.

In a preferred embodiment of the invention the pore-forming agent is selected from the group consisting of potassium hydrogen tartrate (potassium bitartrate), creatine, aspartic acid, glutamic acid and inosine.

25 Other preferred pore-forming agents are chitosan and poly(butyl methacrylate, (2-dimethyl aminoethyl) methacrylate, methyl methacrylate) 1:2:1.

Other pore-forming agents which may be used selected from a group consisting of potassium salts, calcium
30 salts, magnesium salts, amino acids, weak acids, carbohydrates, polymers with amino and/or acid functions. Examples are asparagine, glutamine, leucin, neroleucine, isoleucine, magnesium citrate, magnesium phosphate, magnesium carbonate, magnesium hydroxide, magnesium oxide or a
35 composition wherein at least one component is selected from one of these substances.

The pore-former can also be a composition wherein at least one of the components is selected from one of these groups.

The film-forming polymer according to the present invention could be any pharmaceutically acceptable water insoluble or essentially insoluble polymer, block- or copolymer that can be dispersed in an aqueous solution. Example of such polymers are polymers selected from the groups consisting of cellulose esters, acrylic polymers, polyvinyl acetates, polyvinyl chlorides or a composition wherein at least one component is selected from one of the groups.

Preferred substances are polyvinylacetate, polymethylmetacrylate or a terpolymer of vinylchloride, vinylalcohol and vinylacetate. Commercially available latexes, pseudolatexes and polymer emulsions are also possible to use for the coating.

Other preferred coating polymers are ethylcellulose, celluloseacetate, celluloseacetatebutyrate, celluloseacetatepropionate, nitrocellulose, polymethyl-methacrylate, poly(ethylacrylate, methylmetacrylate), polyvinylacetate, polyvinylchloride, polyethylene, polyisobutylene, poly(ethylacrylate, methylmetacrylate, trimethylammonioethylmetacrylatchloride).

In another preferred embodiment of the invention the coating-agent is a water-dispersion of the terpolymer from US 4,557,925, consisting of 80-95% by weight of polyvinylchloride, 0,5-19% by weight of polyvinylacetate and 0,5-10% by weight of polyvinylalcohol.

In another preferred embodiment of the invention the coating polymer is a copolymer consisting of 50-100% by weight of polyvinylchloride and 0-50% by weight of polyvinylacetate.

The weight ratio, amount of pore-forming agent to total weight of the dry coating, depends on the chosen polymer and pore-former and the release pattern desired,

but is normally between 40 and 95, preferably between 50 and 90 and most preferably between 55 and 88% by weight.

A plasticiser may be added to adjust the softening temperature (T_g) of the polymer. The T_g is an important factor for regulating the mechanical properties of the polymer. Examples of suitable plasticisers are acetyl-tributyl citrate, acetyltriethyl citrate, castor oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, glycerin, mono- and diacetylated monoglycerides, polyethylene glycol, propylene glycol, triacetin, triethyl citrate.

The pore-forming agent in the coating suspension is preferably stabilized with one or more ionic, non-ionic or polymer surfactants. Examples of suitable surfactants are diethanolamine, fatty acids, HPMC (hydroxy propyl methyl cellulose), HPC (hydroxy propyl cellulose), monoethanolamine, nonoxynol, octoxynol, oleic acid, poloxamer, polyoxyethylene 50 stearate, polyoxyl fatty acid, polyoxyl hydrocarbon ether, polysorbate, povidone, salts of fatty acids, sodium lauryl sulfate, sorbitan ester, trolamine.

The aqueous dispersion of the polymer and the pore-forming agent may be used to coat solid cores, which in this context includes crystals, granules, pellets, tablets or the like.

The aqueous dispersion of the polymer and the pore-forming agent is preferably spray-coated onto the solid cores.

The obtained, coated cores may be cured with heat or moisture. Thus the coated preparation may be cured at a temperature higher than storage condition and at a humidity that could be specified for a period of time until the curing endpoint is reached. This endpoint is determined by comparing the dissolution profile with the profile from an accelerated storage condition, for example 3 months at 40°C at ambient humidity. The curing may take

place in the coating equipment or in a separate dryer as for example in a drying chamber or a drying vessel.

The drug in the solid core could for example be tranquillizers, antibiotics, hypnotics, antihypertensives, antianginics, analgesics, antiinflammatories, neuroleptics, antidiabetics, diuretics, antikolinergics, antihyperacidics, antiepileptics, ACE inhibitors, β -receptor antagonists and agonists, anaesthetics, anorexiant, antiarrhythmics, antidepressants, anticoagulants, antidiarrhoeotics, antihistamines, antimalarials, antineoplastics, immunosuppressives, antiparkinsonians, antipsychotics, antiplatelets, diuretics or antihyperlipidics.

The drug substance could for example be potassium chloride, theophylline, a theophylline salt, phenylpropanolamine, sodium salicylate, paracetamol, carbidopa, levodopa, diltiazem, enalapril, verapamil, naproxen, pseudoephedrin, nicorandil, oxybutin, morphine, oxycodone or propranolol.

The aqueous suspension of pore-former and polymer can be diluted with an organic solvent up to 20%, preferably up to 10% and most preferably up to 5%. The organic solvent plasticises the polymer to enhance film formation. The organic solvent also decreases the solubility of the pore-former in the suspension. Thus by using a small amount of organic solvent some advantages may be obtained and, compared with the presently used system, the amount of organic solvent can be reduced. According to the preferred embodiment no organic solvent is included.

In its method aspect, the present invention is not limited by the drug or type of drug incorporated in the preparation. Any composition containing any presently known or future discovered orally acting drug may be coated in order to provide the highly advantageous controlled release pharmaceutical preparations of the present invention.

Furthermore, and to the best of our knowledge, the preparations per se including the preferred pore-forming agents mentioned above are not previously known or even suggested.

5 The invention is further illustrated by, but should not be limited to, the following preparations and example.

Example

10 Core

 The composition of the core is shown in table 1. The ingredients are granulated in a high shear mixer, dried and milled thereafter. The material is blended with lubricants and then compressed to tablets in a tablet
15 press.

TABLE 1

Ingredients	(mg/tablet)
Diltiazem hydrochloride	350
Sodium dihydrogen citrate	218
Povidone K25	42,4
Magnesium stearate	12,5
Ethanol*	45,4
Total	623

*Evaporates during the process

20

Coating suspension

 The composition of a coating is shown in table 2. The coating suspension was prepared by adding the polymer dispersion, the pore former (with a specific particle
25 size of 25 μ m) and deionised water to a final content of dry substances of 15% w/w, to a container with continuous stirring.

TABLE 2

Ingredients	(%/coating)	Dry weight (mg)
Polymer dispersion- Polyvinylacetate (wa- ter dispersion)	30	21
Potassium bitartrate (KHT)	70	49
Deionised water*		397*
Total (mg)		70
Total (mg/cm ²)		20

*Evaporates during the process

5

Coating

The cores were coated with the coating suspension in a coating pan. The coated tablets were allowed to dry in the pan for 15 minutes.

10 Different embodiments of the preparation according to the invention, shown in table 3, were made accordingly.

TABLE 3

Batch	Core (Diltiazem) (mg)	Coating				
		Film weight (mg/cm ²)	Pore- former Type (%)		Polymer Type (%)	
1	350	20	KHT ¹	0	PVAc ²	100
2	350	4, 8	KHT ¹	0	PVAc ²	100
3	350	20	KHT ¹	80	PVAc ²	20
4	350	20	KHT ¹	60	PVAc ²	40
5	320 ³	24	KHT ¹	70	P (EA-MMA) ⁴	30

¹ KHT=Potassium bitartrate

² PVAc=Polyvinylacetate

5 ³ 100 mg of Polyethyleneoxid is included in the formulation

⁴ P (EA-MMA)=Poly(ethylacrylate-methylmethacrylate) 2:1

Results

10 Table 4 shows results from an in vitro dissolution test (according to USP 23, paddle method) with the formulations from table 3.

15 Batch number 1 and 2 with no added pore-former have a very slow release pattern. The addition of pore-former (batch 3-5) increases the release rate and makes it possible to design formulations according to a desired release pattern.

20 Batch 2 and 4 had comparable drug-release rates. However, the polymer films from batch 2 ruptured during the analysis. Batch 4 showed much less variability in drug release compared to batch 2 and the polymer film still had good mechanical strength after the analysis.

TABLE 4

Batch	Amount released Diltiazem (%) after x hours (pH 6,8)							Range at 40% re- leased Diltiazem	
	2h	4h	8h	12h	24h	48h	96h	(%)	n
1	0,1	0,1	0,1	0,1	0,1	0,1	0,6	-	6
2	3,7	7,0	14,9	22,2	41,7	89,4	101,3	17,7	3
3	26,8	50,8	81,6	93,2	97,0	-	-	2,2	6
4	0,6	1,5	8,5	19,7	41,2	-	-	3,5	6
5	15,0	35,1	65,1	89,3	101,4	-	-	7,2	6

After the 24 h in vitro dissolution test the tablet
 5 residuals (= the polymer films filled with water) were
 tested for mechanical strength (MS). The force required
 to crack the polymer film was recorded.

The following results were obtained.

10

TABLE 5

Batch	1	2	3	4	5
MS (N)	-	0	20	27	18

The same test performed on preparations according to
 the US patent 5 472 612 demonstrated that the polymer
 films were broken with negligible forces i.e. forces well
 below 1 N.

The following tables show the effect of the particle size on the release rate.

TABLE 6

Batch	Core Diltiazem	Coating	Pore-former			Coating Polymer P (EA-MMA)
			Type	Particle size (μm)	Amount (%)	Amount (%)
A	300	Film Weight (mg/cm^2)	KHT	8	71	29
B	300	20	KHT	14	71	29

5

TABLE 7

Batch	Amount released Diltiazem (%) after x h (pH 6.8)					Range at 40 % released Diltiazem	
	2h	4h	8h	12h	24h	(%)	n
A	11.4	31.6	62.1	82.4	96.9	5.4	6
B	1.8	14.3	36.8	54.1	85.8	4.4	6

Example 2

The following example discloses the stability of the coating according to the present invention.

Cores of Diltiazem, 300 mg, were prepared as previously described and divided into 2 groups. The cores of group 1 were coated with the polymer Eudragit® and the cores of group 2 were coated with the polymer Kollicoat®. Both coatings were prepared with 71% by weight of KHT according to the present invention. The tablets were stability tested for 6 months and the results are shown in the following table 8.

Table 8

X hours	Eudragit, Amount (%) of released Diltiazem after x hours				
	Initial amount	3 months*	3 months**	6 months*	6 months**
2	7.3	9.4	8.0	8.3	8.5
4	25.5	28.6	27.2	27.4	27.9
8	53.3	58.8	58.1	57.7	59.4
12	74.1	79.3	79.6	78.8	81.2
24	97.4	95.6	96.0	96.4	96.2

X hours	Kollicoat, Amount (%) of released Diltiazem after x hours				
	Initial amount	3 months*	3 months**	6 months*	6 months**
2	9.7	9.1	10.2	9.2	10.6
4	27.8	26.7	28.1	26.6	28.9
8	53.2	52.5	55.5	52.3	56.8
12	69.7	69.2	72.0	68.5	72.9
24	89.4	88.7	89.6	87.4	89.8

*25°C/75%RH

5 **40°C ambient humidity

As can be seen both groups demonstrated excellent stability properties even in such severe conditions as 6 months in 40°C.

CLAIMS

1. A method for producing a controlled-release pharmaceutical preparation with a particle-containing coating
5 comprising the steps of:

- a) preparing a drug-containing solid core;
- b) suspending a pore-forming agent having a balanced solubility in an aqueous dispersion of a film-forming, essentially water insoluble polymer in order to form a
10 coating suspension having a predetermined amount of solid particles of the pore-forming agent suspended therein
- c) coating the solid core with the obtained suspension; and
- d) drying the coated tablet

15 2. A method according to claim 1, wherein the solubility of the pore-forming agent is below 100 mg/ml, preferably below 50 and most preferably below 30 mg/ml in the aqueous coating dispersion.

20 3. A method according to any one of the claims 1-2, wherein the mean particle size of the pore-forming agent is 0.1-500 μm , preferably is 0.5-100 μm and most preferably 1-25 μm .

25 4. A method according to any one of the claims 1-3, wherein the pore-forming agent is selected from a group consisting of potassium salts, calcium salts, magnesium salts, amino acids, weak acids, carbohydrates, polymers with amino and/or acid functions or a composition wherein at least one of the components is selected from one of these groups.

30 5. A method according to any one of the claims 1-4, wherein the pore-forming agent is potassium bitartrate, creatine, asparagine, glutamine, aspartic acid, glutamic acid, leucin, neroleucine, inosine, isoleucine, magnesium citrate, magnesium phosphate, magnesium carbonate, magnesium hydroxide, magnesium oxide or a composition wherein
35 at least one component is selected from one of these substances.

6. A method according to any one of the claims 1-5, wherein the pore-forming agent is chitosan and poly(butyl methacrylate, (2-dimethyl aminoethyl) methacrylate, methyl methacrylate) 1:2:1.

5 7. A method according to any of the claims 1-6, wherein the water insoluble polymer is selected from one of the groups of cellulose esters, acrylic polymers, polyvinyl acetates, polyvinyl chlorides or a composition wherein at least one component is selected from one of
10 the groups.

8. A method according to any one of the claims 1-7, wherein the coating polymer is ethylcellulose, celluloseacetate, celluloseacetatebutyrate, celluloseacetatepropionate, nitrocellulose, polymethylmethacrylate,
15 poly(ethylacrylate, methylmetacrylate), polyvinylacetate, polyvinylchloride, polyethylene, polyisobutylene, poly(ethylacrylate, methylmetacrylate, trimethylaminoethylmetacrylatechloride), a block- or copolymer of the polymers or a composition wherein at least one of the
20 components is selected from these polymers.

9. A method according to any one of the claims 1-7, wherein the coating polymer is a copolymer consisting of 50-100% by weight of polyvinyl chloride and 0-50% by weight of polyvinyl acetate.

25 10. A method according to any one of the claims 1-7, wherein the coating polymer is a copolymer consisting of 80-95% by weight of polyvinylchloride, 0,5-19% by weight of polyvinylacetate and 0,5-10% by weight of polyvinylalcohol.

30 11. A method according to any one of the claims 1-10, wherein the solid core includes at least one drug selected from the group consisting of tranquillizers, antibiotics, hypnotics, antihypertensives, antianginas, analgesics, antiinflammatorics, neuroleptics, antidiabetics,
35 diuretics, anticholinergics, antihyperacidics or antiepileptics, ACE inhibitors, β -receptor antagonists and agonists, anaesthetics, anorexiant, antiarrhythmics, antide-

pressants, anticoagulants, antidiarrhoetics, antihistamines, antimalarials, antineoplastics, immunosuppressives, antiparkinsonians, antipsychotics, antiplatelets, diuretics, antihyperlipidics.

5 12. A method according to any one of the claims 1-11, wherein the drug for the solid core is potassium chloride, theophylline, a theophylline salt, phenylpropanolamine, sodium salicylate, choline theophyllinate, paracetamol, carbidopa, levodopa, diltiazem, enalapril, 10 verapamil, naproxen, pseudoephedrin, nicorandil, oxybutin, morphine, oxycodone or propranolol.

 13. A method according to any one of the claims 1-12, wherein the aqueous dispersion includes at most 20%, preferably at most 10% and most preferably at most 5% by 15 weight of organic solvent.

 14. A method according to any one of the claims 1-12, wherein the obtained coated cores are cured with heat or moisture.

 15. A method according to any one of the claims 1-20 17, wherein the pore-former in the coating suspension is stabilized with one or more ionic, non-ionic or polymer surfactants.

 16. A method according to any one of the claims 1-18, wherein the coating polymer is plasticized.

25 17. A controlled-release pharmaceutical preparation including a drug-containing solid core having a coating thereon, said coating essentially consisting of a water insoluble polymer with a predetermined amount of particles of a water soluble, pore-forming agent dispersed 30 therein, wherein the pore-forming agent is selected from the group consisting of potassium bitartrate, creatine, aspartic acid, glutamic acid and inosine.

 18. A controlled-release pharmaceutical preparation including a drug-containing solid core having a coating 35 thereon, said coating essentially consisting of a water insoluble polymer with a predetermined amount of particles of a water soluble, pore-forming agent dispersed

therein, wherein the pore-forming agent is selected from the group consisting of asparagine, glutamine leucin, ne-roleucine, isoleucine, magnesium phosphate, magnesium carbonate, magnesium hydroxide, chitosan and poly(butyl methacrylate, (2-dimethyl aminoethyl) methacrylate, methyl methacrylate) 1:2:1 or a composition wherein at least one component is selected from one of these substances.

19. Preparation according to any one of the claims 17 or 18, wherein the amount of the pore-forming agent is 40-95, preferably 50-90% and most preferably 55-88 % by weight of the total weight of the dry coating.

20. Preparation according to any one of the claims 17-19 wherein the polymer is ethylcellulose, celluloseacetate, celluloseacetatebutyrate, celluloseacetatepropionate, nitrocellulose, polymethylmethacrylate, poly(ethylacrylate, methylmetacrylate), polyvinylacetate, polyvinylchloride, polyethylene, polyisobutylene, poly(ethylacrylate, methylmetacrylate, trimethylaminoethylmetacrylatchloride), a block- or copolymer of the polymers or a composition wherein at least one of the components is selected from these polymers.

21. Preparation according to any one of the claims 17-19, wherein the coating polymer is a copolymer consisting of 50-100% by weight of polyvinyl chloride and 0-50% by weight of polyvinyl acetate.

22. Preparation according to claim 17-19, wherein the coating polymer is a copolymer consisting of 80-95% by weight of polyvinylchloride, 0,5-19% by weight of polyvinylacetate and 0,5-10% by weight of polyvinylalcohol.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00626

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 9/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CA DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5639476 A (BENJAMIN OSHLACK ET AL), 17 June 1997 (17.06.97), column 1, line 56 - column 2, line 18; column 3, line 1 - line 41; column 4, line 55 - line 56, abstract, column 7, line 51 - 54; column 10, line 36 - column 11, line 46; column 13, line 7 - 11; column 14, line 41 - 59; column 16, line 17 - 29; column 16, line 50 - column 17, line 43 --	1-22
X	US 5472712 A (BENJAMIN OSHLACK ET AL), 5 December 1995 (05.12.95), column 2, line 10 - line 17; column 2, line 61 - column 4, line 10; column 5, line 24 - line 29, column 6, line 33 - 48; column 7, line 60 - column 8, line 20; column 11, line 62 - column 13, line 42; column 14, line 7 - 65; abstract --	1-8,11-20

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

2 August 2001

06-08-2001

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

CAROLINA GÓMEZ LAGERLÖF/EE
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00626

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6024982 A (BENJAMIN OSHLACK ET AL), 15 February 2000 (15.02.00), column 6, line 54 - line 59; column 13, line 61 - column 14, line 9, examples 1 - 2 --	1-8, 11-20
A	US 4629619 A (AKE R. LINDAHL ET AL), 16 December 1986 (16.12.86), example 1 -- -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/07/01

International application No.

PCT/SE 01/00626

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5639476 A	17/06/97	AU 686168 B	05/02/98
		AU 6868994 A	09/02/95
		CA 2128591 A,C	28/01/95
		EP 0636366 A	01/02/95
		US 5580578 A	03/12/96
		US 5958459 A	28/09/99
		US 5968551 A	19/10/99
		US 6143353 A	07/11/00
		AT 184786 T	15/10/99
		AU 660512 B	29/06/95
		AU 2967992 A	29/07/93
		BR 9204577 A	03/08/93
		CA 2074309 A	28/07/93
		DE 69230028 D,T	13/04/00
		DK 553392 T	06/03/00
		EG 20307 A	31/10/98
		EP 0553392 A,B	04/08/93
		SE 0553392 T3	
		ES 2141713 T	01/04/00
		GR 3032106 T	31/03/00
		HK 1005687 A	00/00/00
		HU 66961 A	30/01/95
		HU 218657 B	28/10/00
		HU 219350 B	28/03/01
		HU 9300083 D	00/00/00
		IL 102851 A	10/06/97
		JP 5201856 A	10/08/93
		MX 9205823 A	01/07/93
		NO 309360 B	22/01/01
		NO 924597 A	28/07/93
		NZ 245298 A	26/07/95
		PL 171376 B	30/04/97
		PL 297534 A	18/10/93
		RU 2127587 C	20/03/99
		SG 44698 A	19/12/97
		US 5286493 A	15/02/94
		ZA 9206587 A	02/03/93

INTERNATIONAL SEARCH REPORT
information on patent family members

02/07/01

International application No.

PCT/SE 01/00626

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5472712 A	05/12/95	AU 680491 B	31/07/97
		AU 704524 B	29/04/99
		AU 4368797 A	22/01/98
		AU 6484694 A	19/01/95
		CA 2125904 A	24/12/94
		EP 0630646 A	28/12/94
		FI 943022 A	24/12/94
		JP 7138189 A	30/05/95
		NO 942382 A	27/12/94
		US 5968551 A	19/10/99
		AT 196079 T	15/09/00
		AU 652871 B	08/09/94
		AU 3002492 A	01/07/93
		BR 9202982 A	29/06/93
		CA 2061824 A,C	25/06/93
		DE 69231415 D,T	29/03/01
		DK 548448 T	22/01/01
		EG 20083 A	31/05/97
		EP 0548448 A,B	30/06/93
		SE 0548448 T3	
		ES 2152221 T	01/02/01
		FI 921548 A	25/06/93
		IE 920795 A	30/06/93
		IL 101080 A	05/12/96
		JP 3061474 B	10/07/00
		JP 7165609 A	27/06/95
		KR 252188 B	01/05/00
		MX 9200932 A	01/06/93
		NO 925016 A	25/06/93
		NZ 241660 A	26/05/93
		PT 548448 T	30/03/01
		SG 44703 A	19/12/97
		US 5273760 A	28/12/93
		US 5681585 A	28/10/97
		US 5958459 A	28/09/99
		US 6129933 A	10/10/00
		ZA 9201366 A	30/12/92
US 6024982 A	15/02/00	US 6210714 B	03/04/01
		AU 678859 B	12/06/97
		AU 7885594 A	08/06/95
		CA 2136411 A	24/05/95
		EP 0655240 A,B	31/05/95
		FI 945502 A	24/05/95
		HU 70416 A	30/10/95
		HU 9403268 D	00/00/00
		IL 111519 D	00/00/00
		IL 129870 D	00/00/00
		JP 7252140 A	03/10/95
		KR 220163 B	01/09/99
		NO 944470 A	24/05/95
		US 5500227 A	19/03/96
		ZA 9408677 A	04/07/95

Information on patent family members

International application No.

PCT/SE 01/00626

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4629619 A	16/12/86	US 4557925 A	10/12/85
		US 4629620 A	16/12/86